Antibody Drug Conjugates Market

Antibody-drug conjugates or ADCs are a new class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. These targeted agents combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.

By Dec 2019, eight antibody-drug conjugates have received market approval and nearly 100 investigational ADCs are currently in pre-clinical and clinical trials.

The Global Antibody Drug Conjugates Market was valued at USD 2,233.72 million in 2019 and it is expected to reach USD 15,758.26 million by 2027, growing at CAGR of 27.7% during the forecast period of 2020-2027.

Rise in prevalence of cancer, advancement in technology and increase in R&D investment pertaining to cancer treatment are the factors that drive the growth of the Antibody Drug Conjugates Market. However, complex manufacturing process, availability of alternative treatments, and potential side effects might hamper the market growth. Moreover, the increase in R&D investments in developing economies is expected to provide lucrative opportunities for key market players throughout the forecast period.

The report also presents a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027. Report comes with an associated quantitative Data file.

The forecasts cover 4 By Types, 3 Product Types, 4 Technology Types, 6 Application Types, 4 Regions, and 23 Countries.

The report covers the following topics:

• Market Drivers, Restraints, and Opportunities

• Porters Five Forces Analysis

• Pipeline Analysis

• Top Winning Strategies, Top Investment Pockets

• Top 10 Company Profiles, Product Portfolio, and Key Strategies

• COVID-19 Impact on Global Antibody-drug conjugates Market.